Drugs in Dev. Infections and Infectious Diseases
Phase IV
United Kingdom 
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Fundación Huésped
Deal Size : Inapplicable
Deal Type : Inapplicable
ViiV Healthcare Announces Dovato is Effective in Treatment-Naïve HIV
Details : Dovato combines the IST inhibitor, dolutegravir with the NRT inhibitor, lamivudine, is the first and only oral, two-drug, single-tablet regimen available for 12 and older living with HIV.
Product Name : Dovato
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 11, 2024
Lead Product(s) : Dolutegravir Sodium,Lamivudine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Fundación Huésped
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Zoster Vaccine Recombinant, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Shingrix (recombinant zoster vaccine – RZV) is a non-live, recombinant sub-unit vaccine indicated for the prevention of herpes zoster (HZ) in adults aged 50 and over.
Product Name : Shingrix
Product Type : Vaccine
Upfront Cash : Inapplicable
August 23, 2023
Lead Product(s) : Zoster Vaccine Recombinant, Adjuvanted
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tocilizumab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tocilizumab and sarilumab reduce COVID-19 patient mortality by 8.5 percent. The findings come from the REMAP-CAP trial, which evaluates the effect of treatments on a combination of survival and length of time patients need support in an intensive care un...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
July 01, 2021
Lead Product(s) : Tocilizumab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibuprofen
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New study identifies drugs that are safe to use in COVID-19 treatment
Details : Study has found that there is no evidence for or against the use of non-steroidal anti-inflammatory drugs such as ibuprofen for patients with COVID-19.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2020
Lead Product(s) : Ibuprofen
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ibuprofen
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trial to evaluate formulation of ibuprofen treatment for treating severe acute respiratory distress syndrome (ARDS), a complication of COVID-19, has launched in south London.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2020
Lead Product(s) : Ibuprofen
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
